Salarius Pharmaceuticals, Inc.
SLRXNASDAQHealthcare
$0.84
+$0.19(+29.23%)
Market Cap$4924230
P/E Ratio—
52W High$52.95
52W Low$0.515
Salarius Pharmaceuticals, Inc. (SLRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SLRX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 14, 2025EPS Actual
-$1.81
Est. -$33.60 · +94.6%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 14, 2025
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
SLRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 14, 2025 | -$33.60 | -$1.81 | +94.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$33.00 | -$6.75 | +79.5% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$36.00 | -$15.44 | +57.1% | — | — | — |
| ▲ Q1 FY2025 | Mar 21, 2025 | -$34.65 | -$9.90 | +71.4% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$2.40 | -$11.39 | -374.6% | — | — | — |
| ▲ Q3 FY2024 | Aug 9, 2024 | -$803.60 | -$35.53 | +95.6% | — | — | — |
| ▲ Q2 FY2024 | May 13, 2024 | -$803.60 | -$49.18 | +93.9% | — | — | — |
| ▲ Q1 FY2024 | Mar 22, 2024 | -$121.14 | -$26.39 | +78.2% | $0.00B | — | — |
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$1.81
EPS Est.
-$33.60
EPS Surpr.
+94.6%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$6.75
EPS Est.
-$33.00
EPS Surpr.
+79.5%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$15.44
EPS Est.
-$36.00
EPS Surpr.
+57.1%
Revenue
—
Q1 FY2025
Mar 21, 2025Beat
EPS Actual
-$9.90
EPS Est.
-$34.65
EPS Surpr.
+71.4%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$11.39
EPS Est.
-$2.40
EPS Surpr.
-374.6%
Revenue
—
Q3 FY2024
Aug 9, 2024Beat
EPS Actual
-$35.53
EPS Est.
-$803.60
EPS Surpr.
+95.6%
Revenue
—
Q2 FY2024
May 13, 2024Beat
EPS Actual
-$49.18
EPS Est.
-$803.60
EPS Surpr.
+93.9%
Revenue
—
Q1 FY2024
Mar 22, 2024Beat
EPS Actual
-$26.39
EPS Est.
-$121.14
EPS Surpr.
+78.2%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-34.95 | $-34.95 | $-34.95 | 1 |
| Q3 FY2025 | $-33.60 | $-33.60 | $-33.60 | 1 |
| Q1 FY2022 | $-255.00 | $-255.00 | $-255.00 | 10 |
| Q4 FY2021 | $-195.00 | $-195.00 | $-195.00 | 13 |
| Q3 FY2021 | $-170.00 | $-170.00 | $-170.00 | 7 |
| Q2 FY2021 | $-165.00 | $-165.00 | $-165.00 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2022 | $0.0B | $0.0B | $0.0B | 9 |
| Q4 FY2021 | $0.0B | $0.0B | $0.0B | 14 |
| Q3 FY2021 | $0.0B | $0.0B | $0.0B | 8 |
| Q2 FY2021 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 14, 2025 | +94.6% | $1.21 | $1.20 | -0.83% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +79.5% | $8.54 | $8.25 | -3.40% |
| ▲ Q2 FY2025 | May 14, 2025 | +57.1% | $11.70 | $13.05 | +11.54% |
| ▲ Q1 FY2025 | Mar 21, 2025 | +71.4% | $13.44 | $14.30 | +6.40% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -374.6% | $21.15 | $20.70 | -2.13% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +95.6% | $30.90 | $34.50 | +11.65% |
| ▲ Q2 FY2024 | May 13, 2024 | +93.9% | $60.00 | $58.80 | -2.00% |
| ▲ Q1 FY2024 | Mar 22, 2024 | +78.2% | $70.20 | $74.40 | +5.98% |
Q4 FY2025-0.83%
Report Date
Nov 14, 2025
EPS Beat/Miss
+94.6%
Price Before
$1.21
Price After
$1.20
Q3 FY2025-3.40%
Report Date
Aug 12, 2025
EPS Beat/Miss
+79.5%
Price Before
$8.54
Price After
$8.25
Q2 FY2025+11.54%
Report Date
May 14, 2025
EPS Beat/Miss
+57.1%
Price Before
$11.70
Price After
$13.05
Q1 FY2025+6.40%
Report Date
Mar 21, 2025
EPS Beat/Miss
+71.4%
Price Before
$13.44
Price After
$14.30
Q4 FY2024-2.13%
Report Date
Nov 14, 2024
EPS Beat/Miss
-374.6%
Price Before
$21.15
Price After
$20.70
Q3 FY2024+11.65%
Report Date
Aug 9, 2024
EPS Beat/Miss
+95.6%
Price Before
$30.90
Price After
$34.50
Q2 FY2024-2.00%
Report Date
May 13, 2024
EPS Beat/Miss
+93.9%
Price Before
$60.00
Price After
$58.80
Q1 FY2024+5.98%
Report Date
Mar 22, 2024
EPS Beat/Miss
+78.2%
Price Before
$70.20
Price After
$74.40
Avg Beat Reaction+4.19%
Avg Miss Reaction-2.13%
Beat Rate7 / 8 quarters
Largest Move+11.65% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SLRX ends December
Salarius Pharmaceuticals, Inc. (SLRX) most recently reported earnings on November 14, 2025 for Q4 FY2025, posting EPS of $-1.81 — beating the analyst consensus of $-33.60 by +94.6%. SLRX has beaten EPS estimates for 4 consecutive quarters. The next SLRX earnings date is expected around September 1, 2026.
Each quarter, investors track SLRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SLRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SLRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SLRX earnings · 5 questionsSalarius Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. SLRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SLRX historically reports after market close (AMC).
SLRX earnings datewhen is SLRX earningsSLRX next earnings datewhen does SLRX report earningsSLRX earnings calendar
▸ Source: FMP · Salarius Pharmaceuticals, Inc. SEC filings · US GAAP · Salarius Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026